首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1918130

痛風治療市場－2026-2031年預測

Gout Therapeutics Market - Forecast from 2026 to 2031

出版日期: 2026年01月15日 | 出版商:

Knowledge Sourcing Intelligence | 英文 151 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計痛風治療市場將從 2025 年的 29.26 億美元成長到 2031 年的 45.13 億美元，複合年成長率為 7.49%。

預計到2031年，痛風治療市場將以7.49%的複合年成長率穩定成長，主要促進因素包括疾病盛行率上升、生活方式改變以及公眾意識增強。痛風是由尿酸晶體在關節中積聚引起的關節炎，隨著全球患者數量的增加，專門用於控制和緩解痛風症狀的治療方法日益受到重視。痛風盛行率上升、生活方式改變、肥胖率上升、持續的研究、新產品上市、政府支持以及公眾意識增強等因素都在推動市場擴張。

主要市場促進因素

痛風發病率上升

全球痛風盛行率顯著上升，對有效治療方法的需求持續成長。一項基於臨床實務研究資料庫（CPRD）資料的全國性隊列研究（發表於2021年6月的《風濕病年鑑》）顯示，1997年至2021年間（包括新冠疫情期間），痛風盛行率從0.98%上升至2.33%。過去二十年間盛行率翻番，凸顯了需要治療性介入的患者人數不斷增加，也成為推動市場成長的根本動力，因為醫療保健系統正在積極應對日益成長的治療需求。

與肥胖有關

肥胖和痛風是相互關聯的疾病，肥胖被認為是痛風發生的重要危險因子。超重者，尤其是腹型肥胖者，尿酸合成增加，尿酸排泄減少，導致尿酸水平升高，誘發痛風。全球肥胖盛行率的不斷上升預計將顯著推動痛風治療市場的發展。肥胖已達到流行病的程度，每年造成約280萬人死亡。根據《2022年世界肥胖地圖集》，預計到2031年，五分之一的女性和七分之一的男性將患有肥胖症。這意味著，與肥胖相關的痛風病例數量的不斷增加將持續對痛風治療的需求構成壓力。

生活方式因素

生活方式的選擇在痛風的發生、控制和預防中起著關鍵作用。某些行為，例如飲食選擇、飲酒、吸煙和壓力，都可能導致痛風發作或加重症狀。酒精，尤其是啤酒和烈酒，與痛風風險增加密切相關。 2020年，美國21歲以上成年人平均每人每年消費26加侖啤酒和蘋果酒。這種高酒精消費量，加上久坐等生活方式的改變，都是現代社會普遍存在的可改變的風險因素，也是痛風藥物市場成長要素。

提高認知和診斷水平

醫療專業人員和民眾對痛風的認知不斷提高，診斷率也隨之提升。早期準確診斷有助於儘早開始治療，從而推動了痛風藥物的需求。美國疾病管制與預防中心（CDC）關節炎計畫建議了五種有效的自我管理策略，用於治療關節炎及相關症狀，這些策略對痛風患者同樣有益。 5月22日被定為美國的“痛風宣傳日”，旨在提高公眾對痛風不良反應和治療方案的認知。美國國家痛風教育協會、痛風宣傳聯盟和美國腎臟病患者協會等組織正積極進行痛風宣傳活動。這些有組織的宣傳活動和不斷提高的社會意識鼓勵患者尋求適當的醫療干預，從而促進了市場成長。

研究與開發活動

針對痛風治療的研究和臨床試驗的增加，以及隨後產品的上市，預計將推動市場成長。由InventisBio公司開發的D-0120目前正處於治療痛風性關節炎的II期臨床開發階段。由Selecta Biosciences公司開發的用於治療慢性難治性痛風的SEL-212的III期Dissolve計畫已於2023年3月完成，其中Dissolve I和Dissolve II計畫顯示，在50歲及以上患者中，較高劑量組的緩解率具有統計學意義上的顯著提高。這些正在進行的臨床開發表明，業界致力於拓展治療選擇，並滿足痛風治療領域尚未滿足的需求。

市場限制

儘管痛風治療市場呈現成長趨勢，但仍面臨諸多挑戰。痛風需要長期照護和生活方式調整，然而有些患者難以堅持治療方案，尤其是在藥物依從性、飲食調整和健康生活習慣方面。依從性差會增加疾病進展的風險，並因症狀控制不佳而降低治療效果。此外，痛風治療的副作用，從輕微到嚴重不等，也可能限制市場成長。長期使用皮質類固醇可能引起全身性副作用，這可能導致部分患者無法堅持治療。

區域和近期趨勢

由於痛風發病率上升、醫療基礎設施完善以及醫療費用支出不斷成長，預計北美在預測期內將佔據顯著的市場佔有率。美國醫療支出佔GDP的比例從2019年的16.68%成長到2020年的18.82%。默克和梅奧診所等主要市場參與者預計將透過產品改進推動區域市場成長。

近期發展凸顯了持續創新的重要性。 2022年8月，ThinkLogic宣布推出SYNB2081，這是一種與Ginkgo Bioworks合作，利用合成生物技術開發的候選藥物。該藥物旨在降低尿酸水平。在流行病學趨勢、研究進展以及人們對痛風臨床和經濟負擔日益成長的認知的推動下，痛風治療市場持續發展。

本報告的主要優勢：

深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略實現市場滲透的潛力。
市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

歷史資料（2021-2025 年）和預測資料（2026-2031 年）
成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
競爭對手定位、策略和市場佔有率分析
按業務板塊和地區（國家）分類的收入成長和預測分析
公司概況（策略、產品、財務資訊、關鍵趨勢等）

The gout therapeutics market is experiencing steady growth at a 7.49% CAGR through 2031, driven by increasing disease prevalence, lifestyle changes, and enhanced awareness. Gout therapeutics-treatments specifically designed to manage and alleviate symptoms of this arthritis form caused by uric acid crystal buildup in joints-are becoming increasingly critical as patient populations expand globally. Rising gout prevalence, changing lifestyles, higher obesity rates, ongoing research, product launches, government support, and growing public awareness are propelling market expansion.

Primary Market Drivers

Rising Gout Prevalence

Gout prevalence has increased substantially worldwide, creating sustained demand for effective therapeutics. A nationwide cohort study using Clinical Practice Research Datalink data published in the Annals of Rheumatic Diseases in June 2021 demonstrated that gout prevalence climbed from 0.98% in 1997 to 2.33% in 2021, spanning the COVID-19 pandemic. This more than doubling of prevalence over two decades underscores the growing patient population requiring therapeutic intervention and represents a fundamental driver of market growth as healthcare systems address expanding treatment needs.

Obesity Connection

Obesity and gout are interconnected conditions, with obesity recognized as a significant risk factor for gout development. Overweight individuals, particularly those with abdominal obesity, experience increased uric acid synthesis and decreased uric acid excretion, elevating uric acid levels that precipitate gout. The rising global obesity prevalence is contemplated to substantially aid the gout therapeutics market. Obesity has reached epidemic proportions, causing approximately 2.8 million deaths annually. The World Obesity Atlas 2022 estimates that 1 in 5 women and 1 in 7 men will live with obesity by 2031, indicating sustained pressure on gout therapeutics demand as obesity-related gout cases accumulate.

Lifestyle Factors

Lifestyle choices play crucial roles in gout development, management, and prevention. Certain behaviors-including dietary choices, alcohol consumption, smoking, and stress-can contribute to gout onset or exacerbate symptoms. Alcohol, particularly beer and spirits, has been associated with increased gout risk. Individuals aged 21 and above in the United States consumed an average of 26 gallons of beer and hard cider per person in 2020. This substantial alcohol consumption, combined with changing lifestyle patterns such as sedentary behavior adoption, represents a major growth driver for the gout therapeutics market as these modifiable risk factors remain prevalent in modern societies.

Awareness and Diagnosis Improvements

Increased awareness about gout among healthcare professionals and the general population has led to improved diagnosis rates. Early and accurate diagnosis enables timely treatment initiation, promoting gout therapeutics demand. The CDC's Arthritis Program advises five self-management techniques for treating arthritis and related symptoms that may benefit gout patients. May 22 is celebrated as Gout Awareness Day in America to raise public awareness about adverse effects and treatment options. Organizations including the National Gout Education Society, Alliance for Gout Awareness, and American Association of Kidney Patients actively promote gout awareness. These institutional efforts and rising public consciousness are propelling market growth by ensuring patients seek appropriate medical intervention.

Research and Development Activity

Increasing studies and clinical trials for gout treatment, followed by product launches, are anticipated to boost market growth. D-0120 is under phase II clinical development for gouty arthritis, developed by InventisBio. The phase 3 Dissolve program of SEL-212 developed by Selecta Biosciences to treat chronic refractory gout concluded in March 2023, showing statistically significant higher response rates in patients 50 years and above at high doses in Dissolve I and Dissolve II. These ongoing clinical developments demonstrate industry commitment to advancing therapeutic options and addressing unmet medical needs in gout management.

Market Constraints

Despite positive growth trajectories, the gout therapeutics market faces challenges. Gout demands long-term care and lifestyle modifications, yet some patients struggle with treatment plan adherence, including medication compliance, dietary changes, and healthy lifestyle adoption. Non-compliance may compromise therapeutic effectiveness by raising disease progression risk and resulting in insufficient symptom management. Additionally, adverse effects of gout therapeutics-ranging from minor to serious-may limit market growth. Corticosteroids may produce systemic adverse effects when used over extended periods, potentially deterring some patients from sustained treatment.

Regional Dynamics and Recent Developments

North America is expected to hold significant market share during the forecast period, supported by rising gout incidence, strong healthcare infrastructure, and increasing healthcare expenditure. Health expenditure as a U.S. GDP percentage increased from 16.68% in 2019 to 18.82% in 2020. Major market players including Merck & Co. and Mayo Clinic are expected to bolster regional market growth through enhanced products.

Recent developments underscore ongoing innovation. In August 2022, Synglogic Inc. launched SYNB2081, a new drug candidate for gout treatment developed through synthetic biology in collaboration with Ginkgo Bioworks, designed to lower uric acid levels. The gout therapeutics market continues evolving, propelled by epidemiological trends, research advancement, and growing recognition of gout's clinical and economic burden.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Gout Therapeutics Market Segmentation

By Drug Class
NSAIDs
Corticosteroids
Colchicine
Urate-Lowering Agents
Others
By Disease Condition
Acute Gout
Chronic Gout
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GOUT THERAPEUTICS MARKET BY DRUG CLASS

5.1. Introduction
5.2. NSAIDs
5.3. Corticosteroids
5.4. Colchicine
5.5. Urate-Lowering Agents
5.6. Others

6. GOUT THERAPEUTICS MARKET BY DISEASE CONDITION

6.1. Introduction
6.2. Acute Gout
6.3. Chronic Gout

7. GOUT THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL

7.1. Introduction
7.2. Hospital Pharmacy
7.3. Retail Pharmacy
7.4. Online Pharmacy

8. GOUT THERAPEUTICS MARKET BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Spain
- 8.4.5. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacific
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others